Swiss pharmaceutical company Roche has announced a major investment plan worth €47 billion ($50 billion) in the United States. The funding, to be deployed over the next five years, will support job creation, boost research and development, and expand production across several U.S. states.
The move is expected to generate over 12,000 new jobs and establish or expand company operations in California, Indiana, Massachusetts, and Pennsylvania. Roche says the plan reflects its commitment to strengthening healthcare systems and medical innovation in the U.S.
The company’s official statement confirmed that this is one of its largest single-country investments to date.
Expansion Follows Political and Trade Developments
This announcement comes amid growing political pressure from Washington. President Donald Trump has repeatedly urged global companies to build and invest more within the United States.
Earlier this month, the Trump administration unveiled new tariffs aimed at a wide range of imported goods. Swiss-made products faced potential levies of up to 31%. However, following a diplomatic phone call between President Trump and Swiss President Karin Keller-Sutter, the U.S. paused the tariffs. While no direct link was confirmed, the timing of Roche’s announcement and the policy shift has fueled speculation.
The call reportedly centered on economic cooperation and Swiss investment in U.S. industry.
Innovation at the Heart of Roche’s U.S. Plan
Roche plans to build several new sites, including a gene therapy facility in Pennsylvania and a production center focused on weight-loss medication at a yet-to-be-revealed location.
The company also said it would increase exports of medicine produced in the U.S., a move aimed at supporting global supply chains and reducing import dependence.
Thomas Schinecker, CEO of Roche, said:
“This investment confirms our long-term commitment to the U.S. healthcare sector. We believe in growing where we have deep roots and strong partnerships.”
Roche currently operates 15 research centers and 13 manufacturing sites across the U.S., employing over 25,000 workers. By 2030, the company will operate 24 facilities across eight states.
Economic and Strategic Impact
Last year, Roche recorded more than €64 billion in global sales, with €27 billion coming from the U.S. market. This makes the U.S. the company’s largest pharmaceutical market.
The latest investment is expected to boost U.S.-based innovation, speed up drug development, and support the local economy through construction and advanced technology roles.
Experts say this kind of expansion also sends a strong message to policymakers in both countries about the value of mutual investment and diplomatic collaboration.
According to Dr. Lisa Thornton, a healthcare economist at the University of Chicago:
“When a global leader like Roche invests heavily in the U.S., it’s a win-win. It supports American jobs, strengthens supply chains, and brings life-saving treatments closer to the people who need them.”
Balancing Trade Policy and Business Confidence
Roche’s decision may also help stabilize investor confidence. The company’s stock fell nearly 18% last month, largely due to concerns over rising tariffs and potential disruptions in U.S. trade relations.
With the tariffs temporarily on hold and diplomatic talks ongoing, the pharmaceutical giant’s commitment may serve as a stabilizing signal to markets and regulators alike.
The development is seen as a strategic move that blends diplomacy, business foresight, and healthcare advancement. It underscores the importance of strong transatlantic ties and the role of innovation in shaping economic futures.